All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @justincalomese_bsnrn on Instagram · 47s|Watch on Instagram
Full video transcriptClick to expand

Auto-generated transcript of @justincalomese_bsnrn's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Are you between your 30s and 40s and just not feeling the same as you did in your 20s?
  2. 0:04Have you lost your confidence?
  3. 0:05Maybe you gained some weight?
  4. 0:07I have the perfect solution for you that's going to bring you back to how you used to feel
  5. 0:11and a very simple, easy step.
  6. 0:14Starting a GLP1 medication is going to help you lose weight, lose fat, curb your appetite
  7. 0:21and give you that energy that you need to feel like your old self again.
  8. 0:25Do not be afraid of turning 30 or turning 40 or turning 50.
  9. 0:29These medications are going to help you feel your best at any age.
  10. 0:33Age is nothing but a number.
  11. 0:34So starting on either tricepitzide or stomach glue type, combining it with injectable vitamins
  12. 0:39is going to give you that energy and that weight loss that you've been looking for and
  13. 0:43that you need to start this new decade of your life.

@justincalomese_bsnrn's peptide cocktail claims, fact-checked

Dr. Dream

Instagram creator

6.5K viewsView on Instagram

Quick answer

The creator promotes GLP-1 receptor agonists (semaglutide, tirzepatide) alongside compounded injectable vitamins as a combined protocol for age-related fatigue and weight gain in adults aged 30 to 50. While GLP-1 agonists have robust clinical trial evidence for weight reduction in patients with obesity, neither drug is approved for general wellness or age-related symptom management in metabolically healthy individuals. The injectable vitamin component lacks peer-reviewed evidence supporting additive benefit over GLP-1 therapy alone.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @justincalomese_bsnrn's peptide cocktail claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@justincalomese_bsnrn's peptide cocktail claims, fact-checked" from Dr. Dream. We read the clip as a Peptide social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator promotes GLP-1 receptor agonists (semaglutide, tirzepatide) alongside compounded injectable vitamins as a combined protocol for age-related fatigue and weight gain in adults aged 30 to 50.

The reason this review is not generic is the source wording and the canonical claim label "peptides step 1 https docberry com dr dream drdream antiaging." In this clip, the useful excerpt is: "Are you between your 30s and 40s and just not feeling the same as you did in your 20s?" That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Semaglutide carries FDA approval for chronic weight management in adults with BMI 30 or above, or 27 or above with at least one weight-related condition.
People who land here are usually comparing the Compounded Semaglutide claim with DrDream, AntiAging, and Peptides.
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator promotes GLP-1 receptor agonists (semaglutide, tirzepatide) alongside compounded injectable vitamins as a combined protocol for age-related fatigue and weight gain in adults aged 30 to 50.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator promotes GLP-1 receptor agonists (semaglutide, tirzepatide) alongside compounded injectable vitamins as a combined protocol for age-related fatigue and weight gain in adults aged 30 to 50. While GLP-1 agonists have robust clinical trial evidence for weight reduction in patients with obesity, neither drug is approved for general wellness or age-related symptom management in metabolically healthy individuals. The injectable vitamin component lacks peer-reviewed evidence supporting additive benefit over GLP-1 therapy alone.
  • Tirzepatide produced up to 22.5% mean weight reduction in SURMOUNT-1 (Jastreboff et al., 2022, NEJM), but trial participants had BMI of 30 or above with comorbidities, not general age-related fatigue.
  • Semaglutide carries FDA approval for chronic weight management in adults with BMI 30 or above, or 27 or above with at least one weight-related condition. It is not approved for anti-aging or general wellness.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • Tirzepatide produced up to 22.5% mean weight reduction in SURMOUNT-1 (Jastreboff et al., 2022, NEJM), but trial participants had BMI of 30 or above with comorbidities, not general age-related fatigue.
  • Semaglutide carries FDA approval for chronic weight management in adults with BMI 30 or above, or 27 or above with at least one weight-related condition. It is not approved for anti-aging or general wellness.
  • Tirzepatide's prescribing information includes an FDA boxed warning for thyroid C-cell tumors based on rodent data. Any prescriber omitting this in a telehealth intake is not meeting informed consent standards.
  • Compounded injectable vitamin blends (MICC, lipotropic injections) are not FDA-approved drugs. They are not equivalent to any approved formulation and have no large-scale RCT evidence for energy enhancement in non-deficient adults.
  • A 2022 Cochrane review found no reliable evidence that injectable B12 provides additional benefit over oral supplementation in people without confirmed deficiency, which undermines the energy claim for injectable vitamins.
  • Rapid weight loss from GLP-1 therapy is associated with lean muscle mass reduction. A 2023 Obesity Reviews analysis (Bilet et al.) flagged this as a clinically meaningful concern, particularly without resistance training.
  • Fatigue and weight gain in adults aged 30 to 50 have multiple treatable causes including hypothyroidism, sleep apnea, hypogonadism, and dietary patterns. A GLP-1 prescription without ruling these out is not complete clinical care.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @justincalomese_bsnrn actually say?

The pitch is straightforward: if you're between 30 and 50 and "not feeling the same as you did in your 20s," starting a GLP-1 medication combined with injectable vitamins will restore your energy, strip fat, and make "age nothing but a number." He specifically names "tricepitzide" (almost certainly tirzepatide) and "stomach glue type" (semaglutide), and frames them as a gateway to feeling like your "old self again." The video is also a direct funnel to a third-party telehealth link.

To his credit, he does not promise a specific number on the scale, and he does not claim these drugs are risk-free. But the framing is optimistic to the point of being misleading, and the mispronunciation of drug names on a medical professional's platform is a real concern for patient safety.

Does the science back this up?

GLP-1 receptor agonists do produce meaningful weight loss, and the energy benefits are real but indirect. The drugs work. The "cure your 30s malaise" framing does not hold up to scrutiny.

Semaglutide (Wegovy) reduced body weight by an average of 14.9% over 68 weeks in the STEP 1 trial (Wilding et al., 2021, NEJM). Tirzepatide showed even stronger results, with up to 22.5% mean weight reduction at the highest dose in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM). Those are genuinely impressive numbers. But neither trial recruited people based on "not feeling like themselves in their 30s." Participants had clinical obesity or weight-related comorbidities.

On injectable vitamins: the evidence for energy improvement from IV or injectable B-complex and amino acid blends in metabolically healthy people is thin. A 2022 Cochrane review found no reliable evidence that parenteral B12 outperforms oral supplementation in people without deficiency. The "energy" claim here is mostly vibes.

What did they get wrong (or right)?

The drug science is mostly accurate. The lifestyle framing is where things go sideways.

What he got right: GLP-1 agonists do suppress appetite (via hypothalamic GLP-1 receptor activation), promote fat loss, and can improve energy indirectly through weight reduction and better glycemic control. These are documented mechanisms, not hype.

What he got wrong, or at least oversimplified:

  • Framing normal aging between 30 and 50 as a medical problem that requires pharmacological intervention conflates lifestyle factors with pathology. Fatigue and weight gain in this age range have many causes, most of which are not fixed by a GLP-1 alone.
  • "Combining it with injectable vitamins" is presented as a logical stack with synergistic effects. There is no clinical trial evidence supporting this combination for energy or weight loss beyond what the GLP-1 alone produces.
  • Mispronouncing both drug names ("tricepitzide," "stomach glue type") in a video designed to drive prescriptions is a patient safety issue, not a minor slip.
  • The video links to a commercial telehealth platform, which is a conflict of interest that goes undisclosed.

What should you actually know?

GLP-1 medications are not anti-aging drugs, and feeling tired in your 30s is not a GLP-1 deficiency.

If you are clinically overweight or have metabolic risk factors, semaglutide or tirzepatide may be appropriate options to discuss with a licensed provider. The evidence for weight loss is strong. But these drugs carry real side effects: nausea, vomiting, pancreatitis risk, possible thyroid C-cell effects (tirzepatide carries an FDA boxed warning), and muscle mass loss during rapid weight reduction (Bilet et al., 2023, Obesity Reviews).

The "injectable vitamins" component, typically MICC (methionine, inositol, choline, cyanocobalamin) or amino acid blends, is not FDA-approved for weight loss or energy enhancement. These are compounded preparations. They are not equivalent to any approved drug. If a provider is bundling them as part of a weight loss package without explaining this distinction, that is a gap in informed consent.

Age-related fatigue and weight gain between 30 and 50 deserve a real workup: thyroid function, testosterone levels, sleep quality, dietary patterns, stress load. A GLP-1 prescription from a telehealth funnel is not a substitute for that conversation.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Dr. Dream · Instagram creator

6.5K views on this video

Step 1: https://docberry.com/dr-dream/ #DrDream #AntiAging #Peptides #DocBerry #TRT #Longevity #HealthOptimization #MensHealth #Biohacking #biohacking #peptides #bpc157 #micc #lipomino #semaglutid

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about tirzepatide produced up to 22.5% mean weight reduction in surmount-1?

Tirzepatide produced up to 22.5% mean weight reduction in SURMOUNT-1 (Jastreboff et al., 2022, NEJM), but trial participants had BMI of 30 or above with comorbidities, not general age-related fatigue.

What does the video say about semaglutide carries fda approval for chronic weight management in adults?

Semaglutide carries FDA approval for chronic weight management in adults with BMI 30 or above, or 27 or above with at least one weight-related condition. It is not approved for anti-aging or general wellness.

What does the video say about tirzepatide's prescribing information includes an fda boxed warning for thyroid?

Tirzepatide's prescribing information includes an FDA boxed warning for thyroid C-cell tumors based on rodent data. Any prescriber omitting this in a telehealth intake is not meeting informed consent standards.

What does the video say about compounded injectable vitamin blends (micc, lipotropic injections)?

Compounded injectable vitamin blends (MICC, lipotropic injections) are not FDA-approved drugs. They are not equivalent to any approved formulation and have no large-scale RCT evidence for energy enhancement in non-deficient adults.

What does the video say about a 2022 cochrane review found no reliable evidence?

A 2022 Cochrane review found no reliable evidence that injectable B12 provides additional benefit over oral supplementation in people without confirmed deficiency, which undermines the energy claim for injectable vitamins.

What does the video say about rapid weight loss from glp-1 therapy?

Rapid weight loss from GLP-1 therapy is associated with lean muscle mass reduction. A 2023 Obesity Reviews analysis (Bilet et al.) flagged this as a clinically meaningful concern, particularly without resistance training.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Not medical advice. This video was made by Dr. Dream, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.